chloroquine has been researched along with AIDS-Related Opportunistic Infections in 5 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine has been reported to be endowed with anti-HIV-1 activity." | 2.41 | The potential place of chloroquine in the treatment of HIV-1-infected patients. ( Boelaert, JR; Piette, J; Sperber, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laurens, MB | 1 |
| Mungwira, RG | 1 |
| Nyirenda, OM | 1 |
| Divala, TH | 1 |
| Kanjala, M | 1 |
| Muwalo, F | 1 |
| Mkandawire, FA | 1 |
| Tsirizani, L | 1 |
| Nyangulu, W | 1 |
| Mwinjiwa, E | 1 |
| Taylor, TE | 1 |
| Mallewa, J | 1 |
| Blackwelder, WC | 1 |
| Plowe, CV | 1 |
| Laufer, MK | 1 |
| van Oosterhout, JJ | 1 |
| Boelaert, JR | 2 |
| Piette, J | 1 |
| Sperber, K | 1 |
| Appelberg, R | 1 |
| Gomes, MS | 1 |
| Blasi, E | 1 |
| Mazzolla, R | 1 |
| Grosset, J | 1 |
| Lounis, N | 1 |
| Soteriadou, K | 1 |
| Thiakaki, M | 1 |
| Taramelli, D | 1 |
| Tognazioli, C | 1 |
| Kamya, MR | 1 |
| Kigonya, CN | 1 |
| McFarland, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi[NCT01650558] | 1,499 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Occurrence of adverse events that are greater than or equal to Grade 3 that require discontinuation of TS or CQ prophylaxis (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 0 |
| Chloroquine (CQ) Prophylaxis | 0.24 |
| Discontinuation of Standard of Care (Control Arm) | 0 |
Incidence of bacterial infections and malaria (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 27.8 |
| Chloroquine (CQ) Prophylaxis | 37.4 |
| Discontinuation of Standard of Care (Control Arm) | 36.3 |
Number of Participants with at Least One CD4 Count <200 (NCT01650558)
Timeframe: Every 6 months for 22-66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 23 |
| Discontinuation of Standard of Care (Control Arm) | 27 |
Number of participants who ever have a detectable viral load (>400 copies/ml). (NCT01650558)
Timeframe: Throughout study participation, measured every six months (2-5.5 years).
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 24 |
| Chloroquine (CQ) Prophylaxis | 36 |
| Discontinuation of Standard of Care (Control Arm) | 33 |
Incidence of severe events (composite of death and WHO stage 3 and 4 illness) (NCT01650558)
Timeframe: 22-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 3.3 |
| Chloroquine (CQ) Prophylaxis | 4.2 |
| Discontinuation of Standard of Care (Control Arm) | 4.2 |
Incidence of any WHO HIV stage 2, 3, or 4 illness (NCT01650558)
Timeframe: 32-66 months
| Intervention | Events per 100 participant-years (Number) |
|---|---|
| Standard of Care Trimethoprim Sulfamethoxazol (TS) Prophylaxis | 4.0 |
| Chloroquine (CQ) Prophylaxis | 5.7 |
| Discontinuation of Standard of Care (Control Arm) | 5.8 |
1 review available for chloroquine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
The potential place of chloroquine in the treatment of HIV-1-infected patients.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-HIV Agents; Chloroquine; HIV Infections; HIV-1; | 2001 |
1 trial available for chloroquine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Retroviral Agents; Antimalarials; | 2016 |
3 other studies available for chloroquine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Proceedings of the Second International Conference on HIV and Iron. Brugge, Belgium, March 2000.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-HIV Agents; Chloroquine; HIV Infections; HIV-1; | 2001 |
Experimental results on chloroquine and AIDS-related opportunistic infections.
Topics: AIDS-Related Opportunistic Infections; Animals; Cells, Cultured; Chloroquine; Cryptococcus neoforman | 2001 |
HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antimalarials; Child; Child, Preschool; Ch | 2001 |